Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

Cardiovascular Medicine

Clinical Use of Semi-Synthetic Human Skin for Wound Healing

This month, Caroline E. Fife, M.D., Latisha Smith, M.D., Jaime Aristizabal, M.D., Karen Parker, R.N., discuss

CME credit is no longer available for this conference.

Course Authors

Caroline E. Fife, M.D., Latisha Smith, M.D., Jaime Aristizabal, M.D., Karen Parker, R.N.

Dr. Fife has done research supported by NASA, Organogenesis, Inc, Bedfont Scientific Ltd., National Headache Foundation, BristolMyersSquibb, R.W. Johnson Pharmaceuticals and Ciba. Dr. Smith has done research supported by Parke Davis/Warner Lambert, Chrysalis, Inc. and Organogenesis, Inc, and has given lectures supported by Ortho-McNeil.

Dr. Aristizabal and Ms. Parker reports no commercial conflict of interest.

This activity is made possible by an unrestricted educational grant from the Novartis Foundation for Gerontology.

Release Date: 12/08/1999

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Identify the clinical indications for using semi-synthetic human skin in a non-healing wound

  • Describe the proposed mechanism of action of semi-synthetic human skin in effecting wound closure

  • Discuss the basic issues relating to chronic wound management.

 

TERMS AND CONDITIONS

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms.

Courses You Might Like

Current Management of Hypertension

The link between elevated blood pressure and cardiovascular disease is firmly established. How to treat HBP is less certain.
Authors: Aditya Khetan, M.B.B.S., Richard A Josephson, M.S., M.D. and Sri Krishna Madan Mohan M.B.B.S.
View Course
More

Myocardial Infarction

Significant progress has been made in the primary and secondary prevention of myocardial infarction, but it remains a leading cause of death.
Authors: Richard Josephson, M.S., M.D., and Sri K. Madan Mohan, M.D.
View Course
More

Management of Non-Valvular Atrial Fibrillation – The New Era of Oral Anticoagulants

The most important feature which distinguishes AF from other atrial arrhythmias is the absence of P waves.
Authors: Muhib Khan, M.D., and Karen Furie, M.D., M.P.H.
View Course
More

Current Management of Acute Decompensated Heart Failure

The rate of hospitalization for acute decompensated heart failure will continue to increase because of an aging population.
Authors: Joel Schilling, M.D., Ph.D.
View Course
More

Pharmacological Therapy of Cardiac Arrhythmias: Atrial Fibrillation, Current Treatment and Novel Agents

Cardiac arrhythmias may be seen in individuals with known cardiovascular disease (i.e., coronary artery disease (CAD) or valvular abnormalities) or even in those without known cardiac illnesses. The spectrum of cardiac arrhythmias varies between more self-limited or minimally symptomatic findings such as palpitations, which may be associated with premature supraventricular or ventricular beats that many experience, to the more worrisome ventricular fibrillation, a known cause of sudden cardiac arrest for which emergency cardiac resuscitation is required. of cardiac arrhythmias varies between more self-limited or minimally symptomatic findings such as palpitations, which may be associated with premature supraventricular or ventricular beats that many experience, to the more worrisome ventricular fibrillation, a known cause of sudden cardiac arrest for which emergency cardiac resuscitation is required.
Authors: Mohan N. Viswanathan, M.D.
View Course
More

Cardiac Vagal Neurostimulation for Ventricular Rate Control During Atrial Fibrillation

There are two broad strategic treatment options for AF treatment: rhythm control and rate control.
Authors: Youhua Zhang, M.D., Ph.D., and Todor N. Mazgalev, Ph.D.
View Course
More